These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11461124)

  • 1. Sequential antibiotic therapy for cost containment in the hospital setting: why not?
    Lelekis M; Gould IM
    J Hosp Infect; 2001 Aug; 48(4):249-57. PubMed ID: 11461124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous-to-oral antibiotic switch therapy. A cost-effective approach.
    Cunha BA
    Postgrad Med; 1997 Apr; 101(4):111-2, 115-8, 122-3 passim. PubMed ID: 9126207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community-acquired pneumonia. Cost-effective antimicrobial therapy.
    Cunha BA
    Postgrad Med; 1996 Jan; 99(1):109-10, 113-4, 117-9, passim. PubMed ID: 8539197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic streamlining: development and justification of an antibiotic streamlining program.
    Ramirez JA
    Pharm Pract Manag Q; 1996 Oct; 16(3):19-34. PubMed ID: 10166232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989.
    Coleman RW; Rodondi LC; Kaubisch S; Granzella NB; O'Hanley PD
    Am J Med; 1991 Apr; 90(4):439-44. PubMed ID: 1901446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of oral antibiotic therapy.
    Nightingale CH; Quintiliani R
    Pharmacotherapy; 1997; 17(2):302-7. PubMed ID: 9085322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch University Medical Center: a 10-year survey.
    Vriens M; Blok H; Fluit A; Troelstra A; Van Der Werken C; Verhoef J
    Eur J Clin Microbiol Infect Dis; 2002 Nov; 21(11):782-6. PubMed ID: 12461587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of unnecessary i.v. antibiotic days using general criteria for antibiotic switch.
    Waagsbø B; Sundøy A; Paulsen EQ
    Scand J Infect Dis; 2008; 40(6-7):468-73. PubMed ID: 18584533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Modifiability of antibiotic use in a medical clinic].
    Bögli F; Pechula M; Mühlebach S; Conen D
    Schweiz Med Wochenschr; 1996 Nov; 126(48):2078-81. PubMed ID: 8992628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and value of an IV switch.
    Jewesson P
    Pharmacoeconomics; 1994; 5(Suppl 2):20-6. PubMed ID: 10147285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
    Angeli P; Guarda S; Fasolato S; Miola E; Craighero R; Piccolo F; Antona C; Brollo L; Franchin M; Cillo U; Merkel C; Gatta A
    Aliment Pharmacol Ther; 2006 Jan; 23(1):75-84. PubMed ID: 16393283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an antibiotic intravenous to oral sequential therapy program.
    Pablos AI; Escobar I; Albiñana S; Serrano O; Ferrari JM; Herreros de Tejada A
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):53-9. PubMed ID: 15534901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia.
    Paladino JA
    Can J Hosp Pharm; 1995 Oct; 48(5):276-83. PubMed ID: 10152782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Criteria-based antimicrobial i.v. to oral conversion program.
    Okpara AU; Maswoswe JJ; Stewart K
    Formulary; 1995 Jun; 30(6):343-8. PubMed ID: 10144873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost control of therapy for i.v. catheter infections.
    Arnow P
    Hosp Formul; 1993 Jan; 28 Suppl 1():23-7. PubMed ID: 10123834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the Ideal Strategy for Ventilator-associated Pneumonia Prevention. Cost-Benefit Analysis.
    Branch-Elliman W; Wright SB; Howell MD
    Am J Respir Crit Care Med; 2015 Jul; 192(1):57-63. PubMed ID: 25871807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proposal for a shortened i.v. antibiotic treatment as cost-saving measure in the treatment of uncomplicated infections].
    Schmid JP; Regamey C
    Schweiz Med Wochenschr; 1994 Dec; 124(49):2229-33. PubMed ID: 7801083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to cost and fund an infection control programme.
    Mehtar S
    J Hosp Infect; 1993 Sep; 25(1):57-69. PubMed ID: 7901275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic pharmacoeconomics: an attempt to find the real cost of hospital antibiotic prescribing.
    Kerr JR; Barr JG; Smyth ET; O'Hare J; Bell PM; Callender ME
    Ulster Med J; 1993 Apr; 62(1):50-7. PubMed ID: 8516976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial switch therapy.
    Bui K; Quintiliani R
    Conn Med; 1998 Nov; 62(11):665-8. PubMed ID: 9874890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.